Use of Germline BRCA Testing in Patients With Ovarian Cancer and Commercial Insurance

JAMA Netw Open. 2022 Jan 4;5(1):e2142703. doi: 10.1001/jamanetworkopen.2021.42703.

Abstract

This cross-sectional study evaluates changes in the rate of germline BRCA testing among patients with ovarian cancer between 2008 and 2018 and analyzes factors associated with testing rates.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use
  • Cross-Sectional Studies
  • Delayed Diagnosis
  • Early Detection of Cancer
  • Female
  • Genes, Tumor Suppressor
  • Genetic Testing / statistics & numerical data*
  • Humans
  • Insurance, Health*
  • Middle Aged
  • Ovarian Neoplasms* / diagnosis
  • Ovarian Neoplasms* / drug therapy
  • Ovarian Neoplasms* / epidemiology
  • Ovarian Neoplasms* / genetics
  • Practice Patterns, Physicians'

Substances

  • Antineoplastic Agents